1. Introduction {#sec1-jcm-08-00923}
===============

Tuberculosis (TB) remains an important global infectious disease with an estimated 10 million new cases and 1.6 million deaths in 2017 \[[@B1-jcm-08-00923]\]. The World Health Organization (WHO) has set a goal of eradicating TB as a public health problem, aiming to achieve 50% and 90% reductions in the global TB incidence by 2025 and 2035, respectively \[[@B2-jcm-08-00923]\]. TB remains an important infectious disease that causes significant morbidity and mortality \[[@B3-jcm-08-00923]\]. Though considered a treatable infectious disease, TB treatment success rates and cure rates are still suboptimal \[[@B4-jcm-08-00923]\]. The mortality rate from TB remains high, especially in elderly populations, which can exceed 20% in patients older than 65 years \[[@B5-jcm-08-00923]\]. Besides point-of-care diagnostic methods, the discovery of newer anti-TB agents and a more-thorough understanding of its pathophysiology remain important clinical issues in combating this disease.

While the majority of TB studies regarding host immunity have focused on monocytes and lymphocytes, several recent basic science studies have highlighted the role of platelets as a novel participant in TB's pathogenesis \[[@B6-jcm-08-00923]\]. It was first observed that platelet activation status was correlated with TB disease severity \[[@B7-jcm-08-00923]\]. In active TB, a hypercoagulable state exists with an increased risk of thrombosis, which improves after treatment \[[@B8-jcm-08-00923]\]. Furthermore, it is now recognized that platelets play a role in tissue destruction and pro-inflammation in TB disease \[[@B9-jcm-08-00923]\]. In a recent study, active platelets were present at sites of pulmonary TB, and a co-culture with platelets decreased the intracellular killing of *Mycobacterium tuberculosis* and increased its replication \[[@B9-jcm-08-00923]\]. Finally, another more recent study further provided in vivo experimental evidence that infection-induced platelet activation is a potential target for TB host directed therapy \[[@B10-jcm-08-00923]\]. With accumulating evidence of platelet involvement in TB's pathophysiology, it was therefore intriguing to determine if the use of antiplatelet agents would be beneficial for TB patients and could serve as a potential adjunct anti-TB agent. However, no epidemiologic studies have examined this question.

We therefore initiated this population-based study to investigate the clinical impacts of antiplatelet agents on the survival of TB patients. Through the linkage of the Taiwan National Tuberculosis Registry (TNTR) database, the Taiwan National Health Insurance (NHI) database, and national mortality data, we recruited incident TB cases and evaluated whether antiplatelet agents were associated with better outcomes.

2. Experimental Section {#sec2-jcm-08-00923}
=======================

2.1. Ethics Statement {#sec2dot1-jcm-08-00923}
---------------------

The Institutional Review Board of Taipei Medical University approved the study (N201712019) and waved the need for informed consent because this retrospective study used encrypted data and presented no risk to participants.

2.2. Study Participants and Setting {#sec2dot2-jcm-08-00923}
-----------------------------------

This study was conducted by linking Taiwan NHI claims data, mortality data from the Department of Statistics, Ministry of Health, and Welfare, and the TNTR \[[@B11-jcm-08-00923]\]. The TNTR was established by the Taiwan Centers for Disease Control (CDC) in 1996, and clinicians are obligated to report and register every TB patient in Taiwan in the TNTR \[[@B12-jcm-08-00923],[@B13-jcm-08-00923]\]. In addition, the registry system includes information on TB characteristics, treatment courses, and clinical outcomes. Taiwan's NHI is a universal healthcare system that covers 96% of the residents of Taiwan (with a population of about 23 million) \[[@B14-jcm-08-00923],[@B15-jcm-08-00923],[@B16-jcm-08-00923],[@B17-jcm-08-00923]\].

The inclusion criterion was incident TB cases who received anti-TB treatment identified from the TNTR between 2008 and 2014. Patients with multidrug-resistant TB (MDRTB), with incomplete data, or who were younger than 20 years were excluded.

2.3. Definitions and Data Collection {#sec2dot3-jcm-08-00923}
------------------------------------

A diagnosis of TB and information regarding TB disease characteristics (smear positivity, culture positivity, and a cavitation on chest radiography) were ascertained from the TNTR. In Taiwan, a diagnosis of TB is made based on clinical symptoms, microbiological studies, radiographic findings, and response to anti-TB treatment \[[@B18-jcm-08-00923]\]. Comorbidities and clinical characteristics of TB patients were extracted from the Taiwanese NHI claims database.

Antiplatelets were divided into aspirin (ASA, irreversible cyclooxygenase inhibitor) and non-ASA antiplatelets, including adenosine diphosphate (ADP) receptor inhibitors, phosphodiesterase inhibitors, glycoprotein IIB/IIIA inhibitors, and adenosine reuptake inhibitors ([Supplementary Table S1](#app1-jcm-08-00923){ref-type="app"}). Protease-activated receptor (PAR)-1 antagonists and thromboxane receptor antagonists were not available in Taiwan during the study period and were therefore excluded from our study.

Users of each category of drugs were defined as using more than 90 defined daily doses (DDDs) of all drugs in the category within 180 days prior to the TB diagnosis. The calculation of DDD followed its definition by the WHO, which is the assumed average maintenance dose per day for a drug used for its main indication in adults \[[@B19-jcm-08-00923]\].

We collected information (DDD) regarding the usage of statins, metformin, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids within 180 days prior to the TB diagnosis.

The definition of comorbidities is summarized in [Supplementary Table S2](#app1-jcm-08-00923){ref-type="app"}. Immunocompromised hosts were defined if they had either diabetes mellitus (DM), end-stage renal disease (ESRD), cancer, cirrhosis of the liver, steroid use, a transplant, or acquired immunodeficiency syndrome (AIDS).

2.4. Outcomes {#sec2dot4-jcm-08-00923}
-------------

The primary outcome was patient survival after a TB diagnosis. Secondary outcomes were mortality within 12 months after the diagnosis and major bleeding events after the diagnosis.

The definition of major bleeding was modified from the International Society on Thrombosis and Haemostasis (ISTH) definition, and modifications were made due to the limitations of the claims database \[[@B20-jcm-08-00923],[@B21-jcm-08-00923]\]. The definition of major bleeding in our study was hospitalization after TB diagnosis due to either an intracranial hemorrhage or a gastrointestinal hemorrhage necessitating a transfusion. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and ICD-10-CM codes for defining major bleeding are described in [Supplementary Table S3](#app1-jcm-08-00923){ref-type="app"}. The date of hospitalization was the bleeding date.

All participants were followed up until end of the study period (31 December 2016).

2.5. Statistical Analysis {#sec2dot5-jcm-08-00923}
-------------------------

Proportions or means were used to describe the demographic, clinical, and radiographic characteristics of TB patients. Inter-group differences were analyzed using an independent-sample *t*-test for continuous variables and a chi-squared test for categorical variables. The propensity score (PS) for the probability of being administered an antiplatelet agent was derived using a logistic regression model including the potential confounders of age, sex, socioeconomic status, smear positivity, culture positivity, cavitation, comorbidities, the Charlson comorbidity index (CCI) \[[@B22-jcm-08-00923]\], coronary artery disease, DM, ESRD, cancer, cirrhosis, ischemic stroke, chronic obstructive pulmonary disease, AIDS, and hypertension.

A Cox proportional hazard regression model and logistic regression were, respectively, used to analyze factors associated with patient survival and one-year mortality. PS-matching and PS-stratified analysis were both performed. A cumulative incidence function was used to analyze major bleeding events due to competing risks. Variables that remained significantly different after PS matching and accounting for concomitant medications, including statins, steroids, metformin, and NSAIDs, were further adjusted in the final model. We also performed survival and one-year mortality rate analyses before PS matching, adjusted with variables used in the PS derivation. Subgroup analyses were performed among immunocompromised TB patients, including DM, ESRD, psoriasis, cancer, and steroids users. All data analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). *P* \< 0.05 of a two-sided test was considered statistically significant.

3. Results {#sec3-jcm-08-00923}
==========

3.1. Patients Identification {#sec3dot1-jcm-08-00923}
----------------------------

The patient recruitment process is illustrated in [Figure 1](#jcm-08-00923-f001){ref-type="fig"}. In total, 74,753 participants were recruited for the study.

3.2. Demographic Data {#sec3dot2-jcm-08-00923}
---------------------

The clinical characteristics of identified participants are described in [Table 1](#jcm-08-00923-t001){ref-type="table"}. Among 74,753 participants, 12.7% (*n* = 9497) were antiplatelet users, and 10.4% (*n* = 7764) were aspirin users. The mean age was 63.6 years for all participants, and 69.8% were male. Compared to non-users, antiplatelet users were older, more likely to be male, and had higher CCI scores. Antiplatelet users were also more likely to have underlying comorbidities, except for AIDS, rheumatoid arthritis (RA), transplant, and pneumoconiosis. Antiplatelet users were also more likely to be culture positive, but they were less likely to be smear positive or have a cavitation on chest radiography. Antiplatelet users also took a higher cumulative dose of statins, NSAIDs, metformin, and corticosteroids ([Supplementary Table S4](#app1-jcm-08-00923){ref-type="app"}).

After PS matching, 8864 antiplatelet users, including 7281 ASA users and 1704 non-ASA antiplatelet users, were matched with 8864 antiplatelet non-users. As for comorbidities, only the stroke incidence significantly differed between the two groups (26.9% versus 24.5%, *p* \< 0.001). Antiplatelet users also took higher cumulative doses of statins and metformin ([Supplementary Table S4](#app1-jcm-08-00923){ref-type="app"}).

For the subgroup analysis, a 1:1 comparison cohort was created for the ASA (7281 ASA users and 7281 matched antiplatelet non-users) and non-ASA antiplatelet (1704 non-ASA antiplatelet users and 1704 matched antiplatelet non-users) groups from the PS-matched population ([Table 2](#jcm-08-00923-t002){ref-type="table"}). For the ASA subgroup analysis, only the stroke incidence significantly differed between ASA users and matched non-users (24.7% versus 22.6%, *p* = 0.003). ASA users also took higher cumulative doses of statins and metformin and a lower dose of corticosteroids compared to non-users ([Supplementary Table S5](#app1-jcm-08-00923){ref-type="app"}). For the non-ASA antiplatelet subgroup analysis, only ESRD significantly differed between non-ASA antiplatelet users and matched non-users (10.9% versus 8.0%, *p* = 0.005) ([Table 2](#jcm-08-00923-t002){ref-type="table"}). Non-ASA antiplatelet users also took a higher cumulative dose of statins compared to non-users ([Supplementary Table S5](#app1-jcm-08-00923){ref-type="app"}).

3.3. Survival Analysis {#sec3dot3-jcm-08-00923}
----------------------

Before PS matching, antiplatelet use was associated with worse overall survival in the univariate analysis (crude hazard ratio (HR): 1.88, 95% confidence interval (CI): 1.82--1.94, *p* \< 0.0001) but better overall survival in the multivariate analysis (adjusted HR: 0.90, 95% CI: 0.86--0.93, *p* \< 0.0001). After PS matching, antiplatelet use was associated with improved overall survival in the univariate (crude HR: 0.90, 95% CI: 0.87--0.93, *p* \< 0.0001) and multivariate analyses (adjusted HR: 0.91, 95% CI: 0.88--0.95, *p* \< 0.0001). In the PS-stratified analysis, antiplatelet use was associated with improved overall survival (adjusted HR: 0.91, 95% CI: 0.84--0.97, *p* \< 0.0001).

After PS matching, non-ASA antiplatelet use was associated with worse overall survival compared with ASA use (adjusted HR: 1.36, 95% CI: 1.26--1.46, *p* \< 0.0001).

As for the comparison of survival between ASA users and antiplatelet non-users, ASA use was associated with improved overall survival (adjusted HR: 0.90, 95% CI: 0.86--0.94, *p* \< 0.0001) after PS matching.

As for the comparison of survival between non-ASA antiplatelet users and antiplatelet non-users, there was no association between non-ASA antiplatelet use and overall survival (HR: 1.00, 95% CI: 0.92--1.09, *p* = 0.996) after PS matching.

In the subgroup analysis, while immunocompromised patients had worse survival compared with immunocompetent patients (adjusted HR: 1.47, 95% CI: 1.41--1.54, *p* \< 0.0001), antiplatelet use was associated with better survival among both immunocompromised patients (HR: 0.93, 95% CI: 0.89--0.98, *p* = 0.010) and immunocompetent patients (HR: 0.92, 95% CI: 0.86--0.97, *p* = 0.003). Results of the subgroup analysis are illustrated in [Figure 2](#jcm-08-00923-f002){ref-type="fig"}.

3.4. One-Year Mortality Analysis {#sec3dot4-jcm-08-00923}
--------------------------------

Before PS matching, antiplatelet use was associated with a higher one-year mortality rate (crude OR: 1.93, 95% CI: 1.83--2.03, *p* \< 0.0001) in the univariate analysis but a lower one-year mortality rate (adjusted OR: 0.91, 95% CI: 0.85--0.96, *p* = 0.0015) in the multivariate analysis. In the PS-stratified analysis, antiplatelet use was also associated with a lower one-year mortality rate (adjusted OR: 0.90, 95% CI: 0.86--0.93, *p* \< 0.0001).

After PS matching, antiplatelet use was also associated with a lower one-year mortality rate in the univariate analysis (crude OR: 0.87, 95% CI: 0.82--0.93, *p* \< 0.0001) and in the multivariate analysis (adjusted OR: 0.91, 95% CI: 0.85--0.97, *p* = 0.004).

After PS matching, non-ASA antiplatelet use was associated with a higher one-year mortality rate compared with ASA use (adjusted OR: 1.49, 95% CI: 1.32--1.69, *p* \< 0.0001).

As for the comparison of survival between ASA users and antiplatelet non-users, ASA use was associated with a lower one-year mortality rate (adjusted OR: 0.90, 95% CI: 0.83--0.97, *p* \< 0.0001) after PS matching.

As for the comparison of survival between non-ASA antiplatelet users and antiplatelet non-users, there was no association between non-ASA antiplatelet use and the one-year mortality rate (OR: 0.94, 95% CI: 0.82--1.09, *p* = 0.439) after PS matching.

3.5. Major Bleeding Event Analysis {#sec3dot5-jcm-08-00923}
----------------------------------

Incidences of major bleeding were 0.038, 0.035, 0.052, and 0.019 per person-year in antiplatelet users, ASA users, non-ASA antiplatelet users, and antiplatelet non-users, respectively, in the study population before PS matching.

Incidences of major bleeding were 0.037, 0.035, 0.052, and 0.040 per person-year in antiplatelet users, ASA users, non-ASA antiplatelet users, and antiplatelet non-users, respectively, in the study population after PS matching. There was no difference in the bleeding risk between antiplatelet users and non-users in the cumulative incidence function analysis (subhazard ratio: 0.98, 95% CI: 0.90--1.06, *p* = 0.604).

4. Discussion {#sec4-jcm-08-00923}
=============

In our population-based study, we found that antiplatelet use was associated with better overall survival and lower 12-month mortality in pulmonary TB patients who received anti-TB treatment. ASA, which constitutes the majority of antiplatelet agents, provided a survival advantage for TB patients and may be a candidate for auxiliary anti-TB treatment. The safety profile of bleeding events was tolerable among antiplatelet users.

The beneficial effects of antiplatelet agents may result from several mechanisms. First, platelets are known to significantly upregulate monocyte matrix metalloproteinase (MMP)-1 expression, which is associated with lung tissue destruction \[[@B10-jcm-08-00923]\]. In another study, ASA also reduced MMP levels in diabetic rats with induced coronary ischemia \[[@B23-jcm-08-00923]\]. Second, platelets may also act through the modulation of monocyte-derived chemokine and inflammasome activation, leading to a phenotype associated with increased bacterial growth \[[@B9-jcm-08-00923]\]. The increased lung destruction and unrestricted bacterial growth due to platelet activation then leads to poor treatment responses and clinical outcomes. In another murine model study, a low-dose of ASA in combination with other anti-TB agents had anti-inflammatory effects and demonstrated a systemic decrease in neutrophilic recruitment and decreased levels of acute-phase reaction cytokines in the late stage \[[@B24-jcm-08-00923]\]. Interestingly, our study also found that TB disease among antiplatelet users tended not to be cavitated on chest radiography and was also smear negative. This supports antiplatelet agents having beneficial effects of controlling bacterial growth and attenuating lung tissue destruction.

Antiplatelet agents prevent platelet aggregation and are widely used in patients with coronary heart diseases and cerebrovascular events \[[@B25-jcm-08-00923]\]. Different antiplatelet agents inhibit platelet aggregation through different mechanisms. ASA, the most common antiplatelet agent, mainly irreversibly blocks the enzyme cyclooxygenase (COX)-1, thereby preventing the generation of thromboxane A2, a potent platelet activator \[[@B26-jcm-08-00923]\]. Adenosine diphosphate (ADP) antagonists, e.g., clopidogrel, inhibit platelet aggregation by interacting with two purinergic receptors on platelets \[[@B27-jcm-08-00923]\]. A survival advantage was observed in ASA but not in non-ASA antiplatelets. Recently, purinergic pathways were implicated in augmenting the response of killing intracellular pathogens, including *M. tuberculosis,* and also controlling collateral damage \[[@B28-jcm-08-00923]\]. Inhibiting purinergic pathways, as influenced by ADP receptor antagonists, may have adverse impacts on TB treatment. This may explain why a survival benefit was not observed in non-ASA antiplatelet groups. Another explanation may be that non-ASA antiplatelet agents are usually second-line antiplatelets, indicating that non-ASA antiplatelet users may be more disabled or morbid, thus diminishing the benefits of antiplatelet agents. In addition, interestingly, while some basic scientific studies proposed the benefits of ASA, NSAIDs, and even cilostazol in TB treatment, there are no such studies so far that highlighted ADP receptor antagonists as a potential adjunct anti-TB treatment \[[@B29-jcm-08-00923],[@B30-jcm-08-00923],[@B31-jcm-08-00923]\].

Another important and potential explanation for the finding that overall survival did not improve in non-ASA antiplatelet users when compared to antiplatelet non-users may be that the survival benefit was specific to ASA or NSAID effects but not to anti-platelet effects. ASA can modulate inflammatory processes, such as neutrophil attraction and activation, through small lipid mediators such as thromboxane A2 and prostaglandin E2 through COX pathways \[[@B32-jcm-08-00923],[@B33-jcm-08-00923]\]. Interestingly, NSAIDs have been proposed as an adjunct anti-TB treatment by modulating neutrophil recruitment \[[@B34-jcm-08-00923],[@B35-jcm-08-00923]\]. ASA has also been shown before to reduce neutrophil recruitment in active TB diseases \[[@B24-jcm-08-00923]\]. The abovementioned mechanism may also explain why ASA but not non-ASA antiplatelets were associated with improvement in TB survival.

There have been examples of antiplatelet agents being repurposed for other diseases \[[@B26-jcm-08-00923],[@B36-jcm-08-00923],[@B37-jcm-08-00923]\]. An important instance is the use of antiplatelets in chemoprevention and the treatment of colorectal cancer. It was hypothesized that activated platelets contribute to colorectal tumorigenesis and metastatization via cell--cell interactions and release of tumor mediators \[[@B26-jcm-08-00923],[@B36-jcm-08-00923]\]. A low-dose of ASA therefore prevents tumor growth and metastasis by inhibiting platelet activation during different stages of intestinal tumorigenesis \[[@B26-jcm-08-00923],[@B36-jcm-08-00923]\]. As ASA is an old drug with a well-known safety profile, so repurposing ASA use in anti-TB treatment is an attractive approach to improve TB control.

The TNTR is a web-based national TB notification system maintained by the Taiwanese CDC. Since reporting suspected and confirmed TB diseases to the CDC is mandatory and demanded by law in Taiwan, the completeness and timeliness of the TNTR are excellent. Additional patient and disease characteristics, including smear and culture positivity, are available in the database \[[@B38-jcm-08-00923]\]. Uncertain diagnoses of patients also undergo discussion in an expert meeting to ensure the quality of the diagnoses. Linkage between the TNTR, NHI claims database, and mortality data therefore offered the advantage of high diagnostic accuracy, data abundance, and longitudinal follow-ups \[[@B12-jcm-08-00923],[@B39-jcm-08-00923]\].

Bleeding is a concern with use of antiplatelet agents. A low-dose ASA is defined as 75--325 mg daily, and this is the most widely prescribed dosage of ASA used in cardiovascular diseases, but it still carries an increased risk of bleeding \[[@B40-jcm-08-00923]\]. While the vast majority of ASA tablets in Taiwan contain 75--100 mg of ASA, using a DDD of 90 within 180 days as a cutoff point correlated to a daily dose of around 50--100 mg in our study. The bleeding risk in antiplatelet users was not increased in our study, while the survival benefit remained. A low-dose of ASA may, therefore, be considered if ASA is to be used as an auxiliary therapy for TB.

Other concerns remain regarding the use of antiplatelets in anti-TB regimens in addition to the bleeding risk. Drug--drug interactions may also be another issue. For instance, ASA demonstrated a modest antagonism against isoniazid \[[@B41-jcm-08-00923],[@B42-jcm-08-00923]\]. Rifampicin increases the metabolite of clopidogrel, augments antiplatelet activity, and could be associated with a higher bleeding risk \[[@B43-jcm-08-00923]\]. These safety and therapeutic issues should be taken into consideration and evaluated in future studies.

In our study, the benefit of antiplatelet agents was evident among DM, ESRD, psoriasis, and immunocompromised patients. Indeed, diabetes is associated with increased platelet reactivity, and antiplatelet agents are commonly used for the primary and secondary prevention of cardiovascular events \[[@B44-jcm-08-00923],[@B45-jcm-08-00923]\]. ESRD is also associated with the prothrombotic status of platelet dysfunction \[[@B46-jcm-08-00923]\]. In psoriatic patients, an enhanced cyclooxygenase activity with platelelet hyper-aggregation has been observed \[[@B47-jcm-08-00923]\]. In DM, psoriasis, and ESRD patients who develop active TB, the prothrombotic state may be aggravated. In immunocompromised hosts, delayed and impaired innate immune responses to invasion by *M. tuberculosis* are associated with disease status progression, as in the case of DM \[[@B48-jcm-08-00923],[@B49-jcm-08-00923]\]. Furthermore, the treatment of TB patients with underlying comorbidities is a challenge, and treatment outcomes are usually worse. The beneficial effects of antiplatelets in attenuating thrombosis and immunomodulation in DM, psoriasis, ESRD, and immunocompromised patients may be more evident and worthwhile.

Our study has some limitations. First, we were unable to exclude the possibility of unmeasured confounders. For instance, antiplatelet users may have a higher socioeconomic status ([Table 1](#jcm-08-00923-t001){ref-type="table"}) and tend to be more health conscious. This may lead to the earlier detection of TB and better treatment outcomes. We, however, included disease severity and a low income in our PS matching. Furthermore, while antiplatelet agents are mainly used for the primary and secondary prevention of cardiovascular and cerebrovascular diseases, which are usually the result of end organ damage of underlying diseases and aging processes, antiplatelet users may be more fragile and disabled than non-users. Second, our study was conducted in Taiwan, the population of which is of Asian ethnicity. Whether these findings can be extrapolated to patients of other ethnicities remains unknown. In addition, this was a retrospective study, and the conclusions drawn from our study can be speculative. Future interventional studies, especially with a randomized design, should be conducted to prove this finding.

In conclusion, our study is the first population-based epidemiological study that has demonstrated a survival benefit among active TB patients receiving antiplatelets. Our study points to a potential direction for designing and discovering new anti-TB agents. Since ASA use was associated with better overall survival and other antiplatelet drugs did not improve survival rates, this phenomenon may suggest that the survival benefit may not be solely due to antiplatelet effects. Additional studies investigating the underlying mechanisms of antiplatelet treatment against TB and co-morbidities would also be of interest.

5. Data Availability {#sec5-jcm-08-00923}
====================

All data are deposited in Department of Statistics, Ministry of Health and Welfare, Taiwan and are not allowed to exported without application and permission.

We thank the Department of Statistics, Ministry of Health and Welfare, Taiwan for maintaining the dataset.

The following are available online at <https://www.mdpi.com/2077-0383/8/7/923/s1>, Table S1: Antiplatelet agent category and included drugs, Table S2: Definition of comorbidities and other variables, Table S3: ICD-9-CM and ICD-10-CM codes\* used to define intracranial hemorrhage and gastrointestinal bleeding, Table S4: Defined daily doses (DDDs) of drugs in tuberculosis patients with and those without antiplatelet use, Table S5: Defined daily doses (DDDs) of drugs in aspirin users (ASA), non-aspirin antiplatelet users (non-ASA), and non-antiplatelet users (non-users) after propensity-score matching.

###### 

Click here for additional data file.
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###### 

Clinical characteristics of tuberculosis patients with and those without antiplatelet use.

                         Before PS matching   After PS matching                                                                                                                                              
  ---------------------- -------------------- ------------------- -------------- -------------- ---------------- ---------- ---------------- --------------- --------------- --------------- --------------- ----------
  **Age (mean ± SD)**    63.6 ± 18.5          76.1 ± 10.6         75.7 ± 10.7    77.5 ± 9.9     61.7 ± 19.7      \< 0.001   75.9 ± 10.6      75.7 ± 10.6     75.4 ± 10.7     77.2 ± 9.9      76.0 ± 10.6     0.063
  **Male sex**           52,155 (69.8%)       7019 (73.9%)        5702 (73.4%)   1409 (76.0%)   45,136 (69.2%)   \< 0.001   13,059 (73.7%)   6568 (74.1%)    5368 (73.7%)    1295 (76.0%)    6,491 (73.2%)   0.195
  **Low income**         4,005 (5.4%)         303 (3.2%)          250 (3.2%)     59 (3.2%)      3702 (5.7%)      \< 0.001   529 (3.0%)       286 (3.2%)      234 (3.2%)      47 (2.8%)       243 (2.7%)      0.064
  **CCI (mean ± SD)**    3.7 ± 2.1            5.1 ± 2.0           5.0 ± 2.0      5.6 ± 2.1      3.5 ± 2.6        \< 0.001   5.1 ± 2.0        5.1 ± 2.0       4.9 ± 2.0       5.5 ± 2.1       5.1 ± 2.0       0.804
  **CAD**                20,975 (28.1%)       6,571 (69.2%)       5263 (67.8%)   1444 (77.8%)   14,404 (22.1%)   \< 0.001   12,303 (69.4%)   6097 (68.8%)    4911 (67.5%)    1,319 (77.4%)   6206 (70.0%)    0.078
  **Stroke**             6313 (8.5%)          2610 (27.5%)        1968 (25.4%)   655 (35.3%)    3703 (5.7%)      \< 0.001   4550 (25.7%)     2381 (26.9%)    1799 (24.7%)    599 (35.2%)     2169 (24.5%)    \< 0.001
  **DM**                 14,779 (19.8%)       3604 (38.0%)        2950 (38.0%)   717 (38.7%)    11,175 (17.1%)   \< 0.001   6666 (37.6%)     3365 (38.0%)    2775 (38.1%)    654 (38.4%)     3301 (37.2%)    0.329
  **ESRD**               1911 (2.6%)          500 (5.3%)          325 (4.2%)     207 (11.2%)    1411 (2.2%)      \< 0.001   885 (5.0%)       451 (5.1%)      293 (4.0%)      185 (10.9%)     434 (4.9%)      0.581
  **Cancer**             7730 (10.3%)         1086 (11.4%)        839 (10.8%)    253 (13.6%)    6,644 (10.2%)    \< 0.001   1969 (11.1%)     993 (11.2%)     773 (10.6%)     231 (13.6%)     976 (11.0%)     0.702
  **AIDS**               491 (0.7%)           7 (0.1%)            7 (0.1%)       0 (0%)         484 (0.7%)       \< 0.001   10 (0.1%)        7 (0.1%)        7 (0.1%)        0 (0%)          3 (0.03%)       0.343
  **RA**                 1004 (1.3%)          127 (1.3%)          101 (1.3%)     33 (1.8%)      877 (1.3%)       0.996      242 (1.4%)       118 (1.3%)      95 (1.3%)       30 (1.8%)       124 (1.4%)      0.746
  **Psoriasis**          705 (0.9%)           114 (1.2%)          78 (1.0%)      36 (1.9%)      591 (0.9%)       0.007      211 (1.2%)       104 (1.2%)      73 (1.0%)       30 (1.8%)       107 (1.2%)      0.890
  **AS**                 613 (0.8%)           97 (1.0%)           75 (1.0%)      22 (1.2%)      516 (0.8%)       0.023      173 (1.0%)       92 (1.0%)       70 (1.0%)       22 (1.3%)       81 (0.9%)       0.445
  **COPD**               13,187 (17.6%)       2660 (28.0%)        2135 (27.5%)   568 (30.6%)    10,527 (16.1%)   \< 0.001   5045 (28.5%)     2,503 (28.2%)   2,014 (27.7%)   535 (31.4%)     2,542 (28.7%)   0.527
  **Transplant**         135 (0.2%)           24 (0.3%)           17 (0.2%)      8 (0.4%)       111 (0.2%)       0.101      40 (0.2%)        24 (0.3%)       17 (0.2%)       8 (0.5%)        16 (0.2%)       0.268
  **Pneumoconiosis**     69 (0.1%)            13 (0.1%)           11 (0.1%)      \*\*           56 (0.1%)        NS         20 (0.1%)        11 (0.1%)       9 (0.1%)        \*\*            9 (0.1%)        NS
  **Bronchiectasis**     1474 (2.0%)          233 (2.5%)          192 (2.5%)     46 (2.5%)      1241 (1.9%)      \< 0.001   462 (2.6%)       216 (2.4%)      177 (2.4%)      42 (2.5%)       246 (2.8%)      0.172
  **Hypertension**       37867 (50.7%)        8688 (91.5%)        7095 (91.4%)   1717 (92.6%)   29179 (44.7%)    \< 0.001   16259 (91.7%)    8095 (91.3%)    6646 (91.3%)    1572 (92.2%)    8164 (92.1%)    0.064
  **TB severity**                                                                                                                                                                                            
  **Smear positive**     30,257 (40.5%)       3445 (36.3%)        2873 (37.0%)   621 (33.5%)    26,812 (41.1%)   \< 0.001   6731 (38.0%)     3348 (37.8%)    2795 (38.4%)    604 (35.6%)     3383 (38.2%)    0.599
  **Culture positive**   56,383 (75.4%)       7343 (77.3%)        6030 (77.7%)   1389 (74.9%)   49,040 (75.2%)   \< 0.001   13,575 (76.6%)   6784 (76.5%)    5598 (76.9%)    1,263 (74.1%)   6791 (76.6%)    0.915
  **Cavitation**         12,092 (16.2%)       950 (10.0%)         832 (10.7%)    120 (6.5%)     11,142 (17.1%)   \< 0.001   1832 (10.3%)     927 (10.5%)     816 (11.2%)     114 (6.7%)      905 (10.2%)     0.604

Abbreviations: AIDS, acquired immunodeficiency syndrome; AS, ankylosing spondylitis; CAD, coronary artery disease; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; ESRD, end-stage renal disease; NS, non-significant; PS, propensity score; RA, rheumatoid arthritis; SD, standard deviation; and TB, tuberculosis. \* Compared between all antiplatelet users and non-users. \*\* According to the regulations of National Health Insurance claims database, results with case number less than three are not allowed to be exported.
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###### 

Subgroup analysis of aspirin users (ASA), non-aspirin antiplatelet users (non-ASA), and non-antiplatelet users (non-user) after propensity-score matching.

                              ASA (*n* = 7281)   Matched non-user (*n* = 7281)   *p* value   Non-ASA (*n* = 1704)   Matched non-user (*n* = 1704)   *p* value
  --------------------------- ------------------ ------------------------------- ----------- ---------------------- ------------------------------- -----------
  **Age** (mean ± SD)         75.4 ± 10.7        75.7 ± 10.7                     0.072       77.2 ± 9.9             77.6 ± 9.8                      0.244
  **Male sex**                5368 (73.7%)       5317 (73.0%)                    0.349       1295 (76.0%)           1275 (74.8%)                    0.450
  **Low income**              234 (3.2%)         198 (2.7%)                      0.087       47 (2.8%)              43(2.5%)                        0.749
  **CCI**                     4.9 ± 2.0          5.0 ± 2.0                       0.474       5.5 ± 2.1              5.5 ± 2.1                       0.634
  Coronary artery disease     4911 (67.5%)       4990 (68.5%)                    0.166       1319 (77.4%)           1339 (78.6%)                    0.432
  Stroke                      1799 (24.7%)       1647 (22.6%)                    0.003       599 (35.2%)            551 (32.3%)                     0.089
  Diabetes mellitus           2775 (38.1%)       2715 (37.3%)                    0.313       654 (38.4%)            649 (38.1%)                     0.888
  End-stage renal disease     293 (4.0%)         306 (4.2%)                      0.617       185 (10.9%)            136 (8.0%)                      0.005
  Cancer                      773 (10.6%)        778 (10.7%)                     0.914       231 (13.6%)            210 (12.3%)                     0.307
  AIDS                        7 (0.1%)           3 (0.04%)                       0.343       0 (0%)                 0 (0%)                          \> 0.999
  Rheumatoid arthritis        95 (1.3%)          96 (1.3%)                       \> 0.999    30 (1.8%)              27 (1.6%)                       0.789
  Psoriasis                   73 (1.0%)          81 (1.1%)                       0.571       30 (1.8%)              26 (1.5%)                       0.686
  Ankylosing spondylitis      70 (1.0%)          66 (0.9%)                       0.796       22 (1.3%)              15 (0.9%)                       0.321
  COPD                        2014 (27.7%)       2051 (28.2%)                    0.506       535 (31.4%)            533 (31.3%)                     0.971
  Transplant                  17 (0.2%)          14 (0.2%)                       0.719       8 (0.5%)               5 (0.3%)                        0.578
  Pneumoconiosis              9 (0.1%)           8 (0.1%)                        \> 0.999    \*\*                   \*\*                            NS
  Bronchiectasis              177 (2.4%)         203 (2.8%)                      0.194       42 (2.5%)              47 (2.8%)                       0.668
  **Tuberculosis severity**                                                                                                                         
  Smear positive              2795 (38.4%)       2829 (38.9%)                    0.574       604 (35.6%)            609 (35.8%)                     0.886
  Culture positive            5598 (76.9%)       5602 (76.9%)                    0.953       1263 (74.1%)           1272 (74.7%)                    0.754
  Cavitation                  816 (11.2%)        785 (10.8%)                     0.427       114 (6.7%)             120 (7.0%)                      0.735

Abbreviations: AIDS, acquired immunodeficiency syndrome; COPD, chronic obstructive pulmonary disease; CCI, Charlson comorbidity index; NS, non-significant; and SD, standard deviation. \* Compared between all antiplatelet users and non-users. \*\* According to the regulations of National Health Insurance database, results with case number less than three are not allowed to be exported.
